Xtalks

At the cutting edge of digital media, we aim to link professionals with high-quality content in a user-friendly and engaging manner. Our online communities act as centers for knowledge and information sharing, helping industry experts make well-informed decisions.

International

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#810289

United States

#428757

Health/Biotechnology and Pharmaceuticals

#398

Traffic sources

Monthly visitors

Articles

Transforming Immuno-Oncology: A Novel Approach to Targeting the Tumor Microenvironment

2 days ago | xtalks.com | Vera Kovacevic

Cancer remains one of the most significant health challenges, with millions of new cases each year. In the US alone, roughly 1.8 million new cancer cases are diagnosed annually, and the vast majority (~90%) of these are solid tumors (cancers of organs such as the breast, lung or colon). Globally, cancer incidence is on the rise.
How Can Technology Transform Site Operations and Participant Experience in Clinical Research?

3 days ago | xtalks.com | Vera Kovacevic

In today’s fast-paced clinical research landscape, technology is redefining trial operations and participant engagement. Clinical research is encountering increasing pressures to enhance efficiency, lower costs and improve patient outcomes. Digital innovation now acts as the cornerstone for advancement. Intelligent automation and streamlined workflows are driving a paradigm shift in designing, executing and experiencing clinical studies.
Preparing for Potential Pharma Tariffs: BMS and Gilead Announce New Multi-Billion-Dollar US Investments

6 days ago | xtalks.com | Ayesha Rashid

As global industries face US tariff threats from the Trump administration, big pharma is bolstering its US foothold with major investments announced by Bristol Myers Squibb (BMS) and Gilead Sciences this week. On May 5, BMS CEO Christopher Boerner announced the company will invest $40 billion over the next five years in its US operations. The investment is aimed at boosting R&D and expanding manufacturing capabilities.
Trump Signs Executive Order to Promote Made in America Drugs

6 days ago | xtalks.com | Ayesha Rashid

US president Donald Trump signed an executive order on Monday to accelerate drug manufacturing in the US. The order seeks to streamline the regulatory approval process for pharmaceutical plants, cutting red tape and encouraging companies to expand or relocate their production operations domestically. The executive action comes as the Trump administration escalates its pressure on the pharmaceutical industry to reduce reliance on foreign drug manufacturing, particularly from China and India.
Zevaskyn Gets FDA Nod as First Cell Therapy for Rare, Debilitating Skin Disease

6 days ago | xtalks.com | Ayesha Rashid

The FDA has granted approval to Abeona Therapeutics’ Zevaskyn (prademagene zamikeracel, also known as pz-cel), marking it as the first and only cell-based gene therapy approved for the rare skin disease recessive dystrophic epidermolysis bullosa (RDEB). The therapy is described as an autologous cell sheet-based gene therapy that acts as a skin graft.
EU Launches €500M 'Choose Europe for Science' Campaign to Attract Global Talent Amid US Science Cuts

1 week ago | xtalks.com | Ayesha Rashid

The European Union (EU) announced €500 million (roughly $537 million) in incentives to bolster science in Europe. On Monday, European Commission (EC) president Ursula von der Leyen, alongside French president Emmanuel Macron, unveiled the Choose Europe for Science campaign at Sorbonne University in Paris. The program allocates €500 million ($566 million) between 2025 and 2027 to enhance the European Research Council’s capacity to support leading researchers worldwide.
Rare Disease Innovation in an Evolving Industry with Amgen’s Dr. Sumita Bhatta - Episode 207

1 week ago | xtalks.com | Ayesha Rashid

In this episode, Ayesha speaks with Sumita Bhatta, MD, Vice President and Global Development Therapeutic Head of Rare Disease at Amgen. In the conversation, Dr. Bhatta shares insights on how large pharmaceutical companies like Amgen are approaching innovation and patient-centricity in the rare disease space. She also discusses the unique challenges and opportunities in developing therapies for small patient populations and how cross-functional collaboration drives progress in this complex field.
Innovating Gastrointestinal Therapeutics: Science, Strategy and Insight

1 week ago | xtalks.com | Vera Kovacevic

Gastrointestinal (GI) disorders pose major challenges in modern healthcare. In the US, nearly 45 million adults suffer from non‐erosive gastroesophageal reflux disease (GERD), while more than 15 million receive prescription treatments for its erosive form. Non‐erosive GERD shows typical reflux symptoms without visible esophageal damage, whereas erosive GERD causes clear injury to the esophageal lining. Globally, Helicobacter pylori infects about 50% of the world’s population.
Skin Cancer Awareness Month 2025: Protect the Skin You’re In

1 week ago | xtalks.com | Ayesha Rashid

As the weather warms up and the sun shines longer, May marks Skin Cancer Awareness Month 2025. It’s a reminder of the importance of protecting our skin, the body’s largest organ, from one of the most common yet highly preventable cancers. With over 5 million cases diagnosed each year in the US alone, skin cancer is the most common cancer in the country. It affects countless lives, but education and early detection can make all the difference.
Boehringer’s Zongertinib Shows Promising Durability in HER2-Mutated NSCLC

1 week ago | xtalks.com | Ayesha Rashid

New data for Boehringer Ingelheim’s investigational oncology candidate, zongertinib, shows sustained clinical benefits in non-small cell lung cancer (NSCLC) patients with HER2 mutations in the tyrosine kinase domain (TKD). Updated findings from the Phase Ib Beamion LUNG-1 trial included durability of response, building on the clinical evidence supporting zongertinib’s efficacy.